Here are some tweets I found of interest today- Monday, March 13th.
More evidence that molecular/genetic makeup of endometrial CA in blacks explains poorer prognostic factors #SGOMtg— A.C. Evans, MD, PhD (@gynoncdoc) March 13, 2017
Maxwell: High MS7 levels in primary tumor consistently associated with poor outcome in endometrial cancer. #SGOMtg— Don S Dizon (@drdonsdizon) March 13, 2017
Great study from @SArmbrusterMD: physical activity intervention associate w long term wt loss in EC pts at meet the prof #SGOMtg #endcancer— Katie Kurnit (@katiekurnit) March 13, 2017
Burnout in Gynecologic Oncologists
Patient Centered Assessment Tool - Great work done by my friend and fellow advocate Annie Ellis.Fowler Prez Addrs: Physician wellness=Better patient outcomes & Quality care. #SGOMtg We NEED you & we need you 2 take care of yourselves ❤— Annie Ellis (@Stigetta) March 13, 2017
Poster 94: Priorities assessment tool (PAT) to support shared decision making, maximize appt time & increase patient satisfaction #SGOMtg pic.twitter.com/Kj7d1oa46M— Annie Ellis (@Stigetta) March 13, 2017
OV21/PETROC trial. another trial that shows intraperitoneal chemotherapy for #ovariancancer patients is better. #SGOMtg #fightsmarter— Rod Rocconi (@rodrocconi) March 13, 2017
Poster 148: no sig diff b/w bev and IP chemo in PFS or OS in pts with #BRCA positive #ovariancancer #SGOMtg— Myriad myChoice (@MyriadMyChoice) March 13, 2017
ctDNA is the future of precision oncology for GYN patients and beyond! So many possibilities! #SGOMtg #endCancer— Katie Kurnit (@katiekurnit) March 13, 2017
Today we presented secondary endpoint data from our landmark NOVA trial at #SGOMtg. Read our press release for more: https://t.co/l9Hk9HULIa— TESARO, Inc. (@TESAROBIO) March 13, 2017
RucaparibMaintenance niraparib improved outcomes & not detrimental to QoL in heavily pretreated platinum sensitive gBRCAmut and non-gBRCAmut #SGOMtg pic.twitter.com/RGkJxDSkod— Annie Ellis (@Stigetta) March 13, 2017
Latest updates for rucaparib for #ovariancancer in ARIEL2 trial , presented at @SGO_org #SGOMtg : https://t.co/ONXf5WtfMg pic.twitter.com/9TfNQoQ0wu— ecancer (@ecancer) March 13, 2017
As we discuss genetic testing at #SGOMtg, important to remember the personal implications https://t.co/5KbrWG7NCw #ovarian cancer #gyncsm— Dr. Robert Dood (@DrRobDood) March 13, 2017
GPI - Glucose-6-phosphate isomerase
Previs: High GPI levels in patients w ovca associated with worse prognosis. #SGOMtg— Don S Dizon (@drdonsdizon) March 13, 2017
Neoadjuvant ChemotherapyPrevis: GPI: glucose 6-phosphate isomerase. Previs finds that inhibition associated with more cell kill/less tumor burden. #SGOMtg— Don S Dizon (@drdonsdizon) March 13, 2017
Arend: pt w/ #BRCA mutation had lowest DNA damage pathway score after NACT - further investigation needed #sgomtg— Myriad myChoice (@MyriadMyChoice) March 13, 2017
Slides from a Sunday presentation on PARP
Drs. Coleman, Herzog, @DrMatulonis, @ShannonWestin Downloadable Slides Now Available at https://t.co/FOiuvBPJzG from symposium at #SGOMtg pic.twitter.com/OChFoann3G— BioAscend (@BioAscend) March 13, 2017
Thanks for all those tweeting from the meeting especially these folks
Follow the newest #socialmedia stars from @mdandersonnews 4 #gyncancer #SGOMtg updates @DrRobDood @katiekurnit @JDottinoMD @RTylerHillmanMD https://t.co/mVo1TZBt9D— Shannon Westin (@ShannonWestin) March 13, 2017
Looking forward to Tweets from tomorrow's meeting.
Dee Every Day is a Blessing!